KMT2E

Across TCGA pan-cancer cohorts, KMT2E RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of KMT2E’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where KMT2E RNA is more highly expressed in tumor relative to normal tissue. In most cancer types KMT2E is over-expressed in tumor, although a few such as KICH and COAD show the opposite, repressed pattern.

KIRC, LIHC, and CHOL are the cancer types where KMT2E tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KMT2E RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+0.545	<.001	9	view →
LIHC	Female	II,III,IV	+0.991	<.001	6	view →
CHOL	Male	All	+2.233	<.001	5	view →
KICH	Female	All	−1.120	<.001	5	view →
COAD	All	All	−0.381	.003	4	view →
HNSC	All	All	+0.402	.012	3	view →
LUSC	All	All	−0.291	.007	3	view →
KIRP	All	IV	+1.109	.013	2	view →
UCEC	All	All	−0.549	.002	2	view →
PAAD	Male	All	+0.355	.032	2	view →
THCA	All	All	−0.334	.013	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

KMT2E–KIRC

Open the KIRC breakdown →